Importance of diabetes management during the COVID-19 pandemic

References

• Johns Hopkins University & Medicine Coronavirus Resource Center. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). 2021 [cited 2021 Jan 15]. Available from: https://coronavirus.jhu.edu/map.html
   Google Scholar
• Wang B, Li R, Lu Z, et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049–6057.
   PubMedGoogle Scholar
• Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813–821.
   PubMedGoogle Scholar
• Sardu C, D’Onofrio N, Balestrieri ML, et al. Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care. 2020;43(7):1408–1415.
   PubMed Web of Science ®Google Scholar
• Zhu L, She ZG, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(6):1068–1077.
   PubMed Web of Science ®Google Scholar
• Hartmann-Boyce J, Morris E, Goyder C, et al. Diabetes and COVID-19: risks, management, and learnings from other national disasters. Diabetes Care. 2020;43(8):1695–1703.
   PubMed Web of Science ®Google Scholar
• Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813–822.
   PubMed Web of Science ®Google Scholar
• Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8(10):823–833.
   PubMed Web of Science ®Google Scholar
• Mahase E. Covid-19: what have we learnt about the new variant in the UK? BMJ. 2020;371:m4944.
   PubMed Web of Science ®Google Scholar
• Deng X, Garcia-Knight MA, Khalid MM, et al. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv. 2021. Preprint available at: DOI:https://doi.org/10.1101/2021.03.07.21252647.
   Google Scholar
• Callaway E. Could new COVID variants undermine vaccines? Labs scramble to find out. Nature. 2021;589(7841):177–178.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions (cdc.gov). [ updated 2021 May 5; cited 2021 May 10]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html
   Google Scholar
• Zhou J, Tan J. Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China. Metabolism. 2020;107:154216.
   PubMed Web of Science ®Google Scholar
• Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372:n693.
   PubMed Web of Science ®Google Scholar
• Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequalae of COVID-19. Nature. 2021;594(7862):259–264.
   PubMed Web of Science ®Google Scholar
• Chao LC, Vidmar AP, Georgia S. Spike in diabetic ketoacidosis rates in pediatric type 2 diabetes during the COVID-19 pandemic. Diabetes Care. 2021;44(6):1451–1453.
   PubMed Web of Science ®Google Scholar
• Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546–550.
   PubMed Web of Science ®Google Scholar
• Gianchandani R, Esfandiari NH, Ang L, et al. Managing hyperglycemia in the COVID-19 inflammatory storm. Diabetes. 2020;69(10):2048–2053.
   PubMed Web of Science ®Google Scholar
• Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;36(7):e3319.
   PubMed Web of Science ®Google Scholar
• Ghoneim S, Butt MU, Hamid O, et al. The incidence of COVID-19 in patients with metabolic syndrome and non-alcoholic steatohepatitis: a population-based study. Metabol Open. 2020;8:100057.
   PubMedGoogle Scholar
• Bramante C, Tignanelli CJ, Dutta N, et al. Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19. medRxiv. 2020. Preprint available at: DOI:https://doi.org/10.1101/2020.09.01.20185850.
   Google Scholar
• Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab. 2012;16(Suppl S1):S27–S36.
   PubMedGoogle Scholar
• Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ Res. 2020;126(10):1456–1474.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.
   PubMed Web of Science ®Google Scholar
• Silhol F, Sarlon G, Deharo JC, et al. Downregulation of ACE2 induces overstimulation of the renin-angiotensin system in COVID-19: should we block the renin-angiotensin system? Hypertens Res. 2020;43(8):854–856.
   PubMed Web of Science ®Google Scholar
• Singh AK, Gupta R, Ghosh A, et al. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303–310.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Vardeny O, Michel T, et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653–1659.
   PubMed Web of Science ®Google Scholar
• Rubino F, Amiel SA, Zimmet P, et al. New-onset diabetes in Covid-19. N Engl J Med. 2020;383(8):789–790.
   PubMed Web of Science ®Google Scholar
• Yang JK, Lin SS, Ji XJ, et al. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193–199.
   PubMed Web of Science ®Google Scholar
• Gregory JM, Slaughter JC, Duffus SH, et al. COVID-19 severity is tripled in the diabetes community: a prospective analysis of the pandemic’s impact in type 1 and type 2 diabetes. Diabetes Care. 2020;44(2):526–532.
   PubMed Web of Science ®Google Scholar
• Wargny M, Gourdy P, Ludwig L, et al. Type 1 diabetes in people hospitalized for COVID-19: new insights from the CORONADO study. Diabetes Care. 2020;43(11):e174–e177.
   PubMed Web of Science ®Google Scholar
• Sardu C, D’Onofrio N, Balestrieri ML, et al. Hyperglycaemia on admission to hospital and COVID-19. Diabetologia. 2020;63(11):2486–2487.
   PubMed Web of Science ®Google Scholar
• Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–436.
   PubMed Web of Science ®Google Scholar
• Fang L, Karkiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? [letter to the editor]. Lancet Respir Med. 2020;8(4):E21.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Young D, Coupland C, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart. 2020;106(19):1503–1511.
   PubMed Web of Science ®Google Scholar
• de Abajo FJ, Rodríguez-Martín S, Lerma V, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet Diabetes Endocrinol. 2020;395(10238):1705–1714.
   Google Scholar
• Guo X, Zhu Y, Hong Y. Decreased mortality of COVID-19 with renin-angiotensin-aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis. Hypertension. 2020;76(2):e13–e14.
   PubMed Web of Science ®Google Scholar
• Mancia G, Rea F, Ludergnani M, et al. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382(25):2431–2440.
   PubMed Web of Science ®Google Scholar
• Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382(25):2441–2448.
   PubMed Web of Science ®Google Scholar
• Yang G, Tan Z, Zhou L, et al. Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study. Hypertension. 2020;76(1):51–58.
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126(12):1671–1681.
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461–2498.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes—2021. Diabetes Care. 2021;44(Suppl 1):S73–S84.
   PubMed Web of Science ®Google Scholar
• Paul SK, Klein K, Thorsted BL, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14(1):100.
   PubMed Web of Science ®Google Scholar
• Peng XV, McCrimmon RJ, Shepherd L, et al. Glycemic control following GLP-1 RA or basal insulin initiation in real-world practice: a retrospective, observational, longitudinal cohort study. Diabetes Ther. 2020;11(11):2629–2645.
   PubMed Web of Science ®Google Scholar
• Peng XV, Ayyagari R, Lubwama R, et al. Impact of simultaneous versus sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists on HbA1c in type 2 diabetes: a retrospective observational study. Diabetes Ther. 2020;11(4):995–1005.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Diabetes: managing sick days. 2020 [cited 2021 Jan 5]. Available from: https://www.cdc.gov/diabetes/managing/flu-sick-days.html
   Google Scholar
• Pal R, Bhadada SK. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Res Clin Pract. 2020;163:108146.
   PubMed Web of Science ®Google Scholar
• Apicella M, Campopiano MC, Mantuano M, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8(9):782–792.
   PubMed Web of Science ®Google Scholar
• Hariyanto TI, Kurniawan A. Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection. Obes Med. 2020;19:100290.
   Google Scholar
• Lalau JD, Al-Salameh A. Management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(8):666–667.
   PubMed Web of Science ®Google Scholar
• Kosiborod M. Dapagliflozin in Respiratory Failure in Patients With COVID-19 - DARE-19. Presented at the American College of Cardiology Virtual Annual Scientific Session (ACC 2021), May 16, 2021. 2021.
   Google Scholar
• Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–254.
   PubMed Web of Science ®Google Scholar
• Solerte SB, D’Addio F, Trevisan R, et al. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter, case-control, retrospective, observational study. Diabetes Care. 2020;43(12):2999–3006.
   PubMed Web of Science ®Google Scholar
• Hariyanto TI, Kurniawan A. Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression. J Diabetes Metab Disord. 2021;543–550. DOI:https://doi.org/10.1007/s40200-021-00777-4
   PubMed Web of Science ®Google Scholar
• Rodriguez-Fortunez P, Franch-Nadal J, Fornos-Perez JA, et al. Cross-sectional study about the use of telemedicine for type 2 diabetes mellitus management in Spain: patient’s perspective. The EnREDa2 Study. BMJ Open. 2019;9(6):e028467.
   PubMed Web of Science ®Google Scholar
• McGloin H, O’Connell D, Glacken M, et al. Patient empowerment using electronic telemonitoring with telephone support in the transition to insulin therapy in adults with type 2 diabetes: observational, pre-post, mixed methods study. J Med Internet Res. 2020;22(5):e16161.
   PubMed Web of Science ®Google Scholar
• Turner J, Larsen M, Tarassenko L, et al. Implementation of telehealth support for patients with type 2 diabetes using insulin treatment: an exploratory study. Inform Prim Care. 2009;17(1):47–53.
   PubMedGoogle Scholar
• Patel SY, McCoy RG, Barnett ML, et al. Diabetes care and glycemic control during the COVID-19 pandemic in the United States. JAMA Intern Med. 2021. DOI:https://doi.org/10.1001/jamainternmed.2021.3047.
   Web of Science ®Google Scholar
• Liu L, Gu J, Shao F, et al. Application and preliminary outcomes of remote diagnosis and treatment during the COVID-19 outbreak: retrospective cohort study. JMIR Mhealth Uhealth. 2020;8(7):e19417.
   PubMed Web of Science ®Google Scholar
• Ding L, She Q, Chen F, et al. The internet hospital plus drug delivery platform for health management during the COVID-19 pandemic: observational study. J Med Internet Res. 2020;22(8):e19678.
   PubMed Web of Science ®Google Scholar
• González-Molero I, Domínguez-López M, Guerrero M, et al. Use of telemedicine in subjects with type 1 diabetes equipped with an insulin pump and real-time continuous glucose monitoring. J Telemed Telecare. 2012;18(6):328–332.
   PubMed Web of Science ®Google Scholar